

# Andrea L Schaffer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4167991/publications.pdf>

Version: 2024-02-01

68  
papers

1,431  
citations

516710

16  
h-index

377865

34  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1931  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interrupted time series analysis using autoregressive integrated moving average (ARIMA) models: a guide for evaluating large-scale health interventions. <i>BMC Medical Research Methodology</i> , 2021, 21, 58.	3.1	252
2	The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. <i>BMC Research Notes</i> , 2015, 8, 634.	1.4	220
3	Emergency department visits, ambulance calls, and mortality associated with an exceptional heat wave in Sydney, Australia, 2011: a time-series analysis. <i>Environmental Health</i> , 2012, 11, 3.	4.0	121
4	Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. <i>Addiction</i> , 2019, 114, 1026-1034.	3.3	75
5	Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. <i>Osteoporosis International</i> , 2014, 25, 1345-1355.	3.1	54
6	The crux of the matter: Did the ABC's Catalyst program change statin use in Australia?. <i>Medical Journal of Australia</i> , 2015, 202, 591-594.	1.7	53
7	Codeine use and harms in Australia: evaluating the effects of re-scheduling. <i>Addiction</i> , 2020, 115, 451-459.	3.3	47
8	Changes in antibiotic prescribing following COVID-19 restrictions: Lessons for post-pandemic antibiotic stewardship. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1143-1151.	2.4	37
9	Interrupted Time Series Analysis of the Effect of Rescheduling Alprazolam in Australia. <i>JAMA Internal Medicine</i> , 2016, 176, 1223.	5.1	31
10	Antipsychotic drug use in pregnancy: A multinational study from ten countries. <i>Schizophrenia Research</i> , 2020, 220, 106-115.	2.0	30
11	Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants. <i>PLoS ONE</i> , 2018, 13, e0208824.	2.5	29
12	Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 716-722.	2.5	24
13	Changes in sales of analgesics to pharmacies after codeine was rescheduled as a prescription only medicine. <i>Medical Journal of Australia</i> , 2020, 212, 321-327.	1.7	24
14	Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: A study in the five Nordic countries, United States, and Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 913-922.	1.9	23
15	Demographic, social and lifestyle risk factors for cancer registry-notified cancer of unknown primary site (CUP). <i>Cancer Epidemiology</i> , 2019, 60, 156-161.	1.9	19
16	Changes in antidepressant use in Australia: A nationwide analysis (2015-2021). <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 49-57.	2.3	18
17	Pregabalin prescribing patterns in Australian general practice, 2012-2018: a cross-sectional study. <i>BJGP Open</i> , 2021, 5, bjgpopen20X101120.	1.8	17
18	Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1465-1473.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 212-221.	4.7	16
20	An audit of cancer of unknown primary notifications: A cautionary tale for population health research using cancer registry data. <i>Cancer Epidemiology</i> , 2014, 38, 460-464.	1.9	14
21	Health service utilisation and investigations before diagnosis of cancer of unknown primary (CUP): A population-based nested case-control study in Australian Government Department of Veterans Affairs clients. <i>Cancer Epidemiology</i> , 2015, 39, 585-592.	1.9	14
22	Predictors of re-fracture amongst patients managed within a secondary fracture prevention program: a 7-year prospective study. <i>Osteoporosis International</i> , 2015, 26, 543-551.	3.1	14
23	Do human papillomavirus vaccines have any role in newborns and the prevention of recurrent respiratory papillomatosis in children?. <i>Journal of Paediatrics and Child Health</i> , 2007, 43, 579-580.	0.8	13
24	How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population-based study (2006-2014). <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1134-1145.	2.4	13
25	Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia. <i>BMJ Quality and Safety</i> , 2020, 29, 365-373.	3.7	12
26	The use and impact of cancer medicines in routine clinical care: methods and observations in a cohort of elderly Australians. <i>BMJ Open</i> , 2014, 4, e004099.	1.9	11
27	Patterns of care and survival after a cancer of unknown primary (CUP) diagnosis: A population-based nested cohort study in Australian Government Department of Veterans Affairs clients. <i>Cancer Epidemiology</i> , 2015, 39, 578-584.	1.9	11
28	Comparison of Prescribing Patterns Before and After Implementation of a National Policy to Reduce Inappropriate Alprazolam Prescribing in Australia. <i>JAMA Network Open</i> , 2019, 2, e1911590.	5.9	11
29	Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 930-936.	1.0	11
30	Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 14, 100226.	2.9	11
31	Psychotropic medicine prescribing and polypharmacy for people with dementia entering residential aged care: the influence of changing general practitioners. <i>Medical Journal of Australia</i> , 2021, 215, 130-136.	1.7	10
32	Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. <i>Cmaj</i> , 2018, 190, E355-E362.	2.0	9
33	Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016). <i>British Journal of Cancer</i> , 2019, 121, 904-911.	6.4	9
34	Patterns of pregabalin initiation and discontinuation after its subsidy in Australia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1882-1887.	2.4	9
35	Trajectories of antipsychotic use before and during pregnancy and associated maternal and birth characteristics. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 1208-1221.	2.3	8
36	Evidence-Practice Gaps in Postdischarge Initiation With Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2019, 8, e014287.	3.7	8

#	ARTICLE	IF	CITATIONS
37	Potentially inappropriate benzodiazepine use in Australian adults: A population-based study (2014-2017). <i>Drug and Alcohol Review</i> , 2020, 39, 575-582.	2.1	8
38	Adherence to Antiretroviral Regimens in Australia: A Nationwide Cohort Study. <i>AIDS Patient Care and STDs</i> , 2020, 34, 81-91.	2.5	8
39	The impact of influenza A(H1N1)pdm09 compared with seasonal influenza on intensive care admissions in New South Wales, Australia, 2007 to 2010: a time series analysis. <i>BMC Public Health</i> , 2012, 12, 869.	2.9	7
40	The impact of permissive and restrictive pharmaceutical policies on quetiapine dispensing: Evaluating a policy pendulum using interrupted time series analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 439-446.	1.9	7
41	Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 40-48.	2.0	7
42	Health-related predictors of cancer registry-notified cancer of unknown primary site (CUP). <i>Cancer Epidemiology</i> , 2019, 61, 1-7.	1.9	6
43	Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 97-105.	1.9	6
44	Evidence-practice gaps in P2Y <sub>12</sub> inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population-level data linkage in Australia. <i>Internal Medicine Journal</i> , 2022, 52, 249-258.	0.8	6
45	Australian Suicide Prevention using Health-Linked Data (ASHLi): Protocol for a population-based case series study. <i>BMJ Open</i> , 2020, 10, e038181.	1.9	6
46	Diagnostic and health service pathways to diagnosis of cancer-registry notified cancer of unknown primary site (CUP). <i>PLoS ONE</i> , 2020, 15, e0230373.	2.5	6
47	The changing face of Australian data reforms: Impact on pharmacoepidemiology research. <i>International Journal of Population Data Science</i> , 2021, 6, 1418.	0.1	6
48	Prescribed medicine use and extent of off-label use according to age in a nationwide sample of Australian children. <i>Paediatric and Perinatal Epidemiology</i> , 2022, 36, 726-737.	1.7	6
49	Validating a proxy for disease progression in metastatic cancer patients using prescribing and dispensing data. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e246-e252.	1.1	5
50	Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia. <i>PLoS ONE</i> , 2022, 17, e0269482.	2.5	5
51	Embracing the full spectrum of real-world data for cancer medicines research in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 186-187.	1.1	3
52	Antiplatelet therapy within 30 days of percutaneous coronary intervention with stent implantation. <i>Medical Journal of Australia</i> , 2020, 213, 124-125.	1.7	2
53	Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 893-902.	2.5	2
54	Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine use. <i>Pain</i> , 2022, 163, e614-e621.	4.2	2

#	ARTICLE	IF	CITATIONS
55	Coming to grips with seemingly conflicting results in programme evaluation: the devil's in the detail. <i>BMJ Quality and Safety</i> , 2021, 30, 70-71.	3.7	1
56	Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study. <i>Public Health Research and Practice</i> , 2015, 25, e2521518.	1.5	1
57	Gabapentinoids: repeating mistakes of the past?. <i>Addiction</i> , 0, , .	3.3	1
58	Monitoring emerging prescription drug related harms: a comment on Cairns <i>et al</i> . (2018) in reply. <i>Addiction</i> , 2019, 114, 572-573.	3.3	0
59	Anticipating the effects of restricting high-dose preparations of strong opioids in Australia: A population-based analysis to inform the current policy debate. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 521-527.	1.9	0
60	Patterns of opioid use in older people diagnosed with cancer in New South Wales, Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 360-370.	1.9	0
61	Real-world data to advance HER2-targeted cancer medicines research: Playing to the strengths of clinical registry and administrative data. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 414-415.	1.1	0
62	Using Australia's National Data Linkage Demonstration Project (NDLDP) to improve cardiac care: Towards a national, whole-of-population linked data resource for evidence-informed health policy. <i>International Journal of Population Data Science</i> , 2018, 3, .	0.1	0
63	Assessing the impact of implementing multiple adherence measures to antiretroviral therapy from dispensing data: a short report. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2022, , 1-6.	1.2	0
64	The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 370-378.	1.9	0
65	Title is missing!. , 2020, 15, e0230373.		0
66	Title is missing!. , 2020, 15, e0230373.		0
67	Title is missing!. , 2020, 15, e0230373.		0
68	Title is missing!. , 2020, 15, e0230373.		0